Inotiv (NOTV) Peer Comparison

$0.01

$-0.07 (-86.23%)

As on 02-Jul-2026 09:30EDT

Market cap

$3 Mln

Revenue (TTM)

$507 Mln

P/E Ratio

--

P/B Ratio

0

Div. Yield

0 %

Edit

	Inotiv (NOTV)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Market cap ($ Mln)	3	16,765	16,261	13,492	11,994
Revenue ($ Mln)	507	2,782	1,054	2,436	670
Net Profit ($ Mln)	-86.97	491.50	755.85	860.62	-319.95
Net Margin (%)	-17.14	17.67	71.69	35.33	-47.79
RoE (%)	-81.62	110.09	--	42.98	-71.14
Price to Earnings	--	35.25	19.00	17.40	--
Price-To-Book	0.01	39.29	9.76	7.42	26.87

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Inotiv (NOTV)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Operating Revenue	507.36	2,782.29	1,054.37	2,435.92	669.50
Cost of Revenue	432.76	1,982.07	103.47	85.67	19.14
Gross Profit	65.05	760.62	588.53	2,236.43	829.45
Operating Expenses	119.61	216.81	841.45	1,378.74	895.93
Operating Profit (EBIT)	-45.01	583.40	109.45	971.51	-226.44
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-105.74	598.92	101.11	1,035.47	-252.08
Provision for Tax	-18.77	107.42	-654.74	174.84	20.05
Profit after Tax (Net Income)	-86.97	491.50	755.85	860.62	-319.95
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Inotiv (NOTV)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Shareholder's Funds	77.10	433.86	1,435.90	1,843.76	465.53
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Non-Current Liabilities	85.03	187.89	384.48	288.55	1,362.63
Current Liabilities	540.29	1,435.43	464.70	361.93	283.35
Total Liabilities	771.11	1,975.47	1,302.02	2,844.42	1,385.30

Assets ($ Mln)

	Inotiv (NOTV)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Non-Current Assets	557.95	1,006.90	895.24	1,243.41	440.60
Current Assets	144.47	1,050.29	1,389.84	1,250.82	1,671.41
Total Assets	771.11	1,975.47	1,302.02	2,844.42	1,385.30
Total Debt*	487.77	120.10	449.89	165.93	864.07
Net Current Assets	-395.82	-385.14	0.00	888.90	1,388.07

Cashflow ($ Mln)

	Inotiv (NOTV)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Cash From Operating Activities	-10.46	713.22	51.77	884.27	179.55
Cash Flow from Investing Activities	-12.89	-31.14	-8.15	350.44	-129.29
Cash from Financing Activities	23.70	-860.39	34.89	-969.59	74.01
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Inotiv (NOTV)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
ROCE (%)	-10.93	53.56	-30.01	32.82	-0.17
ROE (%)	-81.62	110.09	163.18	42.98	-71.14
ROA (%)	-8.19	15.64	26.53	29.32	-16.12
EBIT Margin (%)	-8.99	21.13	5.73	31.04	-0.77
Net Margin (%)	-17.14	17.67	71.69	35.33	-47.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Inotiv (NOTV)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Revenue Growth (%)	5.61	24.67	114.85	9.23	12.22
EBIT Growth (%)	10.70	18.70	136.39	-3.99	93.17
Net Profit Growth (%)	0.57	17.50	378.76	42.89	-115.58
EPS Growth (%)	20.77	26.84	353.27	50.42	-73.87
Book Value Growth (%)	-52.04	164.02	816.12	-0.70	-13.57

Valuation Ratios

	Inotiv (NOTV)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Price / Earnings	-0.73	36.06	-59.76	15.79	-2,869.63
Price / Book Value	0.37	35.44	-80.42	5.72	10.04
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	21.48	28.08	-121.54	12.44	25.04
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Inotiv (NOTV)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debt to Equity	0.00	0.00	0.00	0.00	1.77
Short term debt to equity ratio	5.58	0.00	0.05	0.00	0.09
Current Ratio	0.27	0.73	2.99	3.46	5.90
Quick Ratio	0.19	0.73	2.32	3.38	5.90
Interest Coverage	-0.86	--	1.62	--	-1.72

Operating Efficiency Ratios

	Inotiv (NOTV)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debtors to sales (%)	14.72	15.88	21.25	13.74	1.28
Asset Turnover	0.48	0.89	0.37	0.83	0.34
Receivable days	62.26	50.42	85.52	43.48	1.50
Inventory Days	26.05	--	1,056.70	96.17	--
Payable days	33.45	6.26	331.01	147.97	221.81
Cash Conversion Cycle	54.86	--	811.21	-8.32	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly